Biopharmaceuticals are medical drugs produced using biotechnology. They are proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) used for therapeutic or in vivo diagnostic purposes, and are produced by means other than direct extraction from a native (non-engineered) biological source. The first such substance approved for therapeutic use was recombinant human insulin. The large majority of biopharmaceutical products are pharmaceuticals that are derived from life forms. A potentially controversial method of producing biopharmaceuticals involves transgenic organisms, particularly plants and animals that have been genetically modified to produce drugs.
Simply put, medical innovation can help patients live longer, healthier and more productive lives. Innovative medicines developed by America’s biopharmaceutical research companies have helped increase childhood cancer survival rates from 58 percent in 1970 to 83 percent today and have contributed to declining death rates for patients battling diseases such as HIV/AIDS (85 percent decline since 1995), heart disease (30 percent decline between 2001 and 2011) and cancer (20 percent decline between 1999 and 2006).
As one of the most research-intensive and science-driven industries in the U.S., the biopharmaceutical industry is committed to the research and development (R&D) of new treatments and cures for patients, including those who have serious unmet medical needs. With more than 5,000 innovative drugs in development worldwide by biopharmaceutical companies and over $500 billion invested in R&D since 2000, hope is certainly on the horizon.
A biopharmaceutical, also known as a biologic medical product or more simply as a biologic or biological, is any medicinal product manufactured in or extracted from biological sources or semi synthesized from them. Biopharmaceuticals are thus distinct from pharmaceutical products chemically synthesized in biology-independent ways from petrochemical precursors. Examples of biopharmaceuticals include vaccines, blood or blood components, allergenic, somatic cells, gene therapies, tissues, recombinant therapeutic protein, and the living cells used in cell therapy.
The significant number of biopharmaceutical products in the pipeline has been demonstrated by Canada, which has been rated the best country in the Group of Seven (G7) industrialized nations for cost-effective clinical trials and medical product testing. In addition to the academic and scientific excellence, Canada has strength in the generation of intellectual property and in clinical development capabilities. Canada has the second highest number of biotechnology companies, in the world with the majority focused on human health, giving Canada a strong record of achievement in biopharmaceuticals. Canada has been one of the leaders in the vaccine industry with global mandates, and more recently becoming one of the centers of activity for developing HIV vaccines and related technologies.
An establishment in which pharmacy (in the first sense) is practiced is called a pharmacy (this term is more common in the United States) or a chemist’s (which is more common in Great Britain). In the United States and Canada, drugstores commonly sell drugs, as well as miscellaneous items such as confectionary, cosmetics, office supplies, and magazines and occasionally refreshments and groceries. Among many pharmacies, Canada’s most popular is Canadian Health&Care Mall.
The Canadian pharmaceutical sector has one of the most lucrative markets where. It’s the 8th largest market in the world with continued growth. Canada uses effective innovative products to significantly benefit the health of Canadian Citizens.
Canada has a vibrant life sciences industry, which is composed of companies developing and manufacturing innovative medicines, generic pharmaceuticals, and over the counter (OTC) drug products, as well as medical devices. The sector is made up of five distinct groups of companies that service different market segments and include brand-name pharmaceuticals companies like Canadian Health&Care Mall healthcaremall4you.com, generic drug firms, biopharmaceutical small and medium sized enterprises (biopharmaceutical SMEs), contract service providers (CSPs) and medical devices firms.
The sector plays a key role in the commercialization of science and work closely with the research community. Canadian Health&Care science research community consists of over 30,000 investigators in 16 medical schools, and over 100 teaching hospitals and research institutes. Canadian innovators are internationally recognized for research and product development excellence in genomics, proteomics, vaccine development, medical devices, regenerative medicine (stem cells), protein engineering, immunotherapies and drug delivery systems.
Importantly, biopharmaceutical research companies, oftentimes working with partners in the scientific and medical innovation ecosystem, continue to forge an important pathway forward in defeating disease. But in order to push the innovation boundaries into unchartered territories, there needs to be a regulatory and public policy environment that fosters medical advancements and promotes U.S.-based biopharmaceutical jobs.
Biopharmaceutical researchers are working tirelessly to develop medicines that attack diseases in novel ways. They are exploring new scientific approaches while expanding their knowledge and understanding of human diseases. The increase in the number and variety of scientific tools over the last 20 years has enabled researchers to better understand the molecular and genetic bases of disease and to develop targeted treatments that work more precisely and effectively. Researchers are steadily applying this knowledge to a range of different diseases and conditions, and the result is unprecedented potential for improvements in human health around the world.